TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06504290
Drug: VV119 Placebo （in adult patients with schizophrenia）
Approvals — FDA: no, EMA: no, PMDA: no
Description: VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
Study: NCT05507112
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
Study: NCT06503237
Drug: Anti-CD19 CART cells will be given IV at split doses.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
Study: NCT06175949
Drug: HRS-7085 simulant
Normalized name: STAPHYLOCOCCUS SIMULANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
Study: NCT06086340
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitor Therapy
Study: NCT04219046
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily
Study: NCT04927169
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT06358651
Drug: Fasedienol Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray delivered 20 minutes before the PSC
Study: NCT06358651
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray delivered 20 minutes before the PSC
Study: NCT06478706
Drug: ETD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses
Study: NCT06478706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses
Study: NCT05624580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
Study: NCT05302336
Drug: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide).
Study: NCT05819866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match the study drug visually and by taste
Study: NCT04495608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
Study: NCT06153758
Drug: Danuglipron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron oral tablets
Study: NCT06048484
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)
Study: NCT05037279
Drug: Bacillus Calmette-Guerin: Strain Russian BCG-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Study: NCT05037279
Drug: Bacillus Calmette-Guerin: Strain TICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Study: NCT05373914
Drug: Control: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 250mg tablets (orally)
Study: NCT05410873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06522828
Drug: SSGJ-707
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
Study: NCT05538663
Drug: Bacillus Calmette Guerin
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
Study: NCT05254184
Drug: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
Approvals — FDA: no, EMA: no, PMDA: no
Description: administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
Study: NCT06333964
Drug: AST-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-001, PO bid for 24weeks (dosage according to weight range)
Study: NCT06333964
Drug: Placebo of AST-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
Study: NCT06480968
Drug: CTH120
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition).
Study: NCT05473923
Drug: Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
Study: NCT04366115
Drug: AVM0703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
Study: NCT04366115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion in normal saline over 1 hour to patients.
Study: NCT04595682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
Study: NCT05067140
Drug: ARV-766 Part A&B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles.
Study: NCT06145308
Drug: larotinib or enttraitinib
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po;
Study: NCT06145308
Drug: antiandrogen drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po ± Abiraterone 1000mg po qdor antiandrogen drug treatment; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment;
Study: NCT06145308
Drug: HR-positive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abesili 150mg bid po or Piperoxili 125mg qd po, etc CDK4/6 inhibitors + aromatase inhibitors (letrozole 2.5mg qd po or anastrozole 1mg qd po or Exemestane 20mg qd po) or Fluvis Group 0.5mg im q4w;
Study: NCT06145308
Drug: PI3K mutant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI3K inhibitors such as Apelis 300mg qd po + Fluvis group 0.5mg im q4w, etc
Study: NCT06145308
Drug: Homologous Recombination repair defect group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olapalil 300mg bid po or Nilapalil 300mgPARP inhibitors such as qd po or fluzopalil 150mg bid po or pamipalil 60mg bid po;
Study: NCT06145308
Drug: Apalolito vorellizumab group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalolito vorellizumab 5mg/kg+ Platinum dual drug (white purple 260mg/m2 Q3w/ Paclitaxel liposome 175mg/m2/ Docetaxel 75mg/m2/ vinorelbine 25mg/m2 + cisplatin 75mg/m2, Q3w or carboplatin 350mg/m2 q3w) + bevacizumab 5mg/kg;
Study: NCT05480111
Drug: Sham Local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mls of normal saline given at incision site
Study: NCT06261957
Drug: Salbutamol HFA-134a
Normalized name: HYDROFLUOROCARBON 134A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microgram (μg) (ex-valve) at 30-second intervals per actuation
Study: NCT06261957
Drug: Salbutamol HFA-152a
Normalized name: HYDROFLUOROCARBON 152A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg (ex-valve) at 30-second intervals per actuation
Study: NCT05976347
Drug: Fluoxetine 20 MG
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily
Study: NCT06110338
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo iv. once.
Study: NCT06110338
Drug: IBI355
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI355 iv. once.
Study: NCT05891795
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply a thin layer to the affected area twice daily.
Study: NCT06196671
Drug: H101
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: H101 15x10\^11vp intratumorally injection starts at day 1.
Study: NCT05682482
Drug: LT3 (liothyronine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
Study: NCT05682482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
Study: NCT06108544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified drug on specified days.
Study: NCT05660980
Drug: Long acting CAB injectable + long acting RPV injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable
Study: NCT06490718
Drug: USG ESPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle.
Study: NCT06490718
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure.
Study: NCT05212818
Drug: TF0023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
Study: NCT04895241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06262607
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vehicle gel administered once daily
Study: NCT05949502
Drug: Beautifil II LS (Low-Shrinkage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low shrinkage bioactive material Giomer
Study: NCT05949502
Drug: 3M Filtek Z250 XT Universal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal Nano-hybrid composite
Study: NCT05789069
Drug: HFB200603
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered HFB200603 as described in the experimental arm.
Study: NCT06023641
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1
Study: NCT05048524
Drug: S-1, leucovorin, oxaliplatin and gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day
Study: NCT05457829
Drug: Doxorubicin Hydrochloride Liposome+Irinotecan
Normalized name: irinotecan hydrochloride liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W, 2 cycles.
Study: NCT05618691
Drug: GFH312
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
Study: NCT06573528
Drug: CS060380
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05957939
Drug: Alkaline Glucosodiene Molecules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
Study: NCT06190197
Drug: Prophylactic antibiotics postoperatively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
Study: NCT05686044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC (vegetarian source) capsule shells
Study: NCT05219370
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of different cannabis oil types as compared with placebo
Study: NCT00000771
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04986436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose(s) of Placebo
Study: NCT05002244
Drug: CTL0801 (Azilsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL0801 (Azilsartan), single dose, daily, repeated oral administration
Study: NCT05002244
Drug: CTL0802 (Rosuvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
Study: NCT05002244
Drug: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
Study: NCT06205615
Drug: BXP154B
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXP154B will be self-administered topically following wound induction
Study: NCT06205615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be self-administered topically following wound induction
Study: NCT05250063
Drug: LUM-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT06003348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06571045
Drug: EYE103
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYE103 is a humanized antibody formulated for intravitreal administration
Study: NCT05007652
Drug: KRN125(pegfilgrastim), PLR001(plerixafor)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Study: NCT05007652
Drug: KRN8601(filgrastim), PLR001(plerixafor)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Study: NCT05865041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered orally
Study: NCT05433844
Drug: Reference Drug or Test Drug
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Study: NCT05732532
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
Study: NCT00669123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00261404
Drug: TNFerade™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05543772
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: participant will be given 500 ml normal saline through intravenous access. blood sample will be extracted before and after giving normal saline using same intravenous catheter
Study: NCT05753592
Drug: Part 1; LOU064 (Remibrutinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg remibrutinib (5.5 days)
Study: NCT05753592
Drug: Part 2; LOU064 (Remibrutinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg remibrutinib (5.5 days)
Study: NCT04888377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant's mothers were administered placebo throughout their pregnancy with the participant.
Study: NCT04762719
Drug: PET/CT Scan with 11C-ER176
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
Study: NCT06072612
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.